Latest Patent Licensing News

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

DUG Technology reported a 23% surge in software revenue and a 15% rise in EBITDA for FY25-Q3, underpinned by strong services order growth and strategic expansion into Brazil.